Please login to the form below

Not currently logged in
Email:
Password:

rFIXFc

This page shows the latest rFIXFc news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Biogen Idec's haemophilia A therapy

FDA starts review of Biogen Idec's haemophilia A therapy

Eloctate was developed in partnership with Swedish Orphan Biovitrum (Sobi), which also collaborated on the development of Biogen Idec's haemophilia B candidate Alprolix (recombinant factor IX Fc fusion protein; rFIXFc).

Latest news

  • Biogen submits haemophilia drug for US approval Biogen submits haemophilia drug for US approval

    Backing the submission of rFIXFc are results from B-LONG, which Biogen says is the largest phase III clinical study in haemophilia B to date. ... This study demonstrated that rFIXFc was both clinically effective and safe, helping to prevent bleeding

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics